For rapid, selective transmembrane ion flow—the kind underlying electrical signaling in the nervous system and many other cellular processes—membrane-spanning proteins called ion channels were ...
“The problem of selectivity has turned the industry’s attention towards discovering and developing therapeutic antibodies targeting ion channels,” explained Paul Colussi, VP of research at ...
Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® ...
Cambridge biotech Maxion Therapeutics has raised $72 million (£58m) in a Series A financing to further grow the business ...
Our lab studies the physiology, pharmacology and biophysics of ion channels. Ion channel proteins form ion-selective pores within cell membranes and in the heart they establish and maintain normal ...
Cambridge, UK-based biotech start-up Maxion Therapeutics, which is developing antibody-based KnotBody drugs for ion channel- ...
Mechanisms of ion selectivity and throughput in the mitochondrial calcium ... Gating choreography and mechanism of the human proton-activated chloride channel ASOR. Science Advances Jiang, Y., Benz, T ...
A Cambridge-based biotechnology firm developing antibody-based KnotBody drugs for ion channel- and G protein-coupled receptor (GPCR)-driven diseases, has raised £58m in a Series A financing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback